Even if peptide therapy has become more interesting for the wellness and aesthetic market as well as for the field of longevity and is discussed in a clinical setting more and more, there are a number of operational questions that a prescribing doctor has to answer. Of course it is not a question if he is going to use peptides or not, but rather how he can integrate them into his existing program of a patient in a structured way with appropriate entry criteria, appropriate monitoring in between the intakes and appropriate exit criteria.
This is followed by a description of the operational framework that underpins the use of peptide therapies for facilitating measurable clinical change and creating a framework for successful treatment programs that can be used in the long term.
Where peptides sit within a broader program
While it is true that many wellness programs include a single “peptide protocol”, in reality this is typically done in conjunction with efforts to correct other aspects of the patient’s wellness. Thus, a Peptide Protocol is typically part of a larger Wellness Plan which includes strategies to improve sleep, enhance resistance training, ensure proper nutrition, and treat any endocrine or metabolic problems with which the patient may be afflicted.
Sequencing of therapies is very important. If a patient has sleep apnea, very low ferritin levels, or a thyroid that is not quite optimal then these need to be treated first before starting any injectable therapies. Otherwise, it is impossible to tell if any changes that occur were as a result of the peptide therapies or not and the patient pays for treatments that have no benefit.
Setting the objective before the agent
Set a clear target for the peptide therapy and follow the patient up against set measures of success for soft tissue repair, body composition reduction, sleep enhancement and energy. Remember, perceptions of improved health are extremely vague and can be continuously shifted to fit a practitioner’s theories, focus on objective measures that can be charted at each follow-up to provide a clear picture of progress or lack thereof.
Structuring the initial consultation
A useful first appointment is one which lasts for as long as necessary to complete the required work, which typically would be around 45 minutes to an hour. The practitioner must establish whether the proposed program is or is not suitable for the patient and record the various baselines. Practitioners who offer peptide injection as part of a larger service to patients would class the first appointment as the chief risk point and therefore conduct as much useful work as possible to minimize exposure.
- Full medication and supplement review, including anything sourced online or from previous clinics
- Personal and family oncology history, since several growth-related peptides warrant caution here
- Baseline bloods appropriate to the agent, commonly fasting glucose, HbA1c, lipid panel, full blood count, renal and liver function, and IGF-1 where growth hormone secretagogues are considered
- Objective baseline measures tied to the stated goal, for example grip strength, waist circumference, or a validated sleep questionnaire
- Documented discussion of regulatory status, compounding source, and the limits of available evidence
Screening out rather than screening in
It is useful to go into the intake for peptide protocols with a ‘no’ stance and list all of the reasons that would prevent you from prescribing in the first place. Some of the main reasons for not prescribing would include active malignancy, pregnancy, poorly controlled diabetes, significant renal impairment and unstable psychiatric presentation. Patients who want to be prescribed peptides as part of a broader wellness program and are unwilling to engage in the rest of the program are also a high risk to the clinician.
Monitoring intervals and what to measure
Monitoring should correlate with the agent’s mechanism of action and the patient’s risk factors. Short courses of agents for repair of soft tissue in healthy individuals (e.g. 35 years old) will generally require less monitoring than long-term use of secretagogues in individuals with a metabolic syndrome etc. Risk profile.
For patients weighing up where to begin, it is worth choosing a clinic that builds this level of review into the service from the outset, which is the standard anyone considering peptide injections in Jacksonville FL should expect before a first dose is given.
| Stage | Timing | Typical focus | Decision made |
| Baseline | Before first dose | Bloods, goal metrics, injection technique training | Proceed, defer, or decline |
| Early review | 2 to 4 weeks | Tolerability, injection site reactions, adherence | Dose adjustment or discontinue |
| Interim review | 8 to 12 weeks | Repeat relevant bloods, reassess goal metrics | Continue, modify, or stop |
| Course end | 12 to 24 weeks | Full comparison against baseline | Washout, repeat cycle, or exit |
Defining the stopping rule in advance
Establish what conditions will end the protocol prior to commencing. For instance absence of movement in the primary endpoint at the interim review, rise in fasting glucose of more than a few mg/dL, continued fluid retention, or any adverse event that the patient finds unacceptable. These must be written down at the intake prior to the first injection and can form part of the reasons for cessation of the trial period at week twelve.
Documentation, sourcing, and governance
Different compounded peptides are of different quality. The supply chain needs to be able to provide written evidence of the pharmacy’s credentials and CoAs for the different compounds where available. The ability to trace back to the exact batch that was given to that patient must be available within minutes in case of an unexpected reaction to a compounded product.
- Keep a written protocol per agent covering indication, dosing range, contraindications, and review schedule
- Record consent that names the regulatory status and the uncertainty in the evidence base
- Audit outcomes across the patient group quarterly, not just case by case
- Review and update protocols when new safety data emerges, and date each version
Communicating uncertainty well
Being truthful with patients is far better than being arrogant. They respond so much better to a pragmatic and realistic approach and it means you can record that a trial period has been carried out to gather information and that stopping the treatment for whatever reason is OK and does not mean failure.